1.68
+0.16(+10.53%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.5 |
| Day High | 1.68 |
| Day Low | 1.45 |
| 52-Week High | 4.49 |
| 52-Week Low | 0.7 |
| Volume | 1.15M |
| Average Volume | 4.27M |
| Market Cap | 29.22M |
| PE | -2.18 |
| EPS | -0.77 |
| Moving Average 50 Days | 0.98 |
| Moving Average 200 Days | 1.65 |
| Change | 0.16 |
If you invested $1000 in Nexalin Technology, Inc. (NXL) since IPO date, it would be worth $746.67 as of October 21, 2025 at a share price of $1.68. Whereas If you bought $1000 worth of Nexalin Technology, Inc. (NXL) shares 2 years ago, it would be worth $5,773.2 as of October 21, 2025 at a share price of $1.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
GlobeNewswire Inc.
Oct 13, 2025 12:30 PM GMT
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rot
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
GlobeNewswire Inc.
Oct 10, 2025 12:00 PM GMT
HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the u
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
GlobeNewswire Inc.
Oct 08, 2025 12:30 PM GMT
40-Hz DIFS™ significantly improves cognitive performance and brain connectivity in peer-reviewed clinical trial Results published in Radiology, the flagship journal of the Radiological Society of North America (RSNA) HOUSTON, TX, Oct. 08, 2025 (GL